At AF Symposium 2024, we sat down with T. Jared Bunch, MD to discuss trends in atrial fibrillation, practice patterns in usage of intravenous sotalol at the University of Utah and across the country, and more. Tune in and listen in on this insightful conversation! https://lnkd.in/g6Fmi5Pk
AltaThera Pharmaceuticals’ Post
More Relevant Posts
-
I agree that this is a wonderful graphic. I believe we should take a long-term lifetime view of cardiovascular risk. It is the biggest killer, and most risk calculators that are promoted take a short term 5-to-10-year risk view. I am not sure about you, but I know that I am keen to avoid a cardiac event when I am 60 but I am also keen to avoid one when I am 70 or 80 (if I get there!). Lifetime risk is the most important and we have effective tools to reduce cardiovascular events and death: starting with lifestyle measures, progressing to pills and injectables and then if that fails to various procedures that are available. The biggest hurdle is usually to start. So be proactive. See your healthcare team and discuss with them how to best assess and manage your cardiovascular risk. Advara HeartCare
Just published in JACC Journals was a SADLY not open-access paper on the 5- year data from FOURIER OLE on the incredible ability of evolocumab in reducing MACE in ASCVD patients. Even better was the editorial which had this great graphic - the editorialists stated - "prevention of ASCVD is a marathon - one that requires long-term focus, intensity, commitment, attention, & persistence." I say - folks can "pay the primary prevention doc now or pay the cardiologist/undertaker later." Please respect apoB. Study & editorial is at https://lnkd.in/eyQbtFxg and editorial at https://lnkd.in/eQhjcCwA National Lipid Association European Atherosclerosis Society European Society of Cardiology
To view or add a comment, sign in
-
MD | First Gen Doctor | Obstetrics and Gynecology Resident at Dubai Health | Medical influencer & Content Creator
Special thanks to Dr. Iman Alshamsi joining us from 🇦🇪 and making an outstanding contribution to medical knowledge. Her expertise in nephrology, particularly in discussing end-stage kidney disease, provides valuable insights for all healthcare professionals. Join us in expressing gratitude for her engaging conversation on the complexities of nephrology. 🎙️ #MedicalPodcast #Nephrology #MedSynapse"
Explore the world of nephrology with our latest MedSynapse podcast featuring Dr. Iman Alshamsi, a distinguished Nephrology Consultant /Internal Medicine Consultant at SEHA Kidney Care. As a member of the American Society of Nephrology and Emirates Medical Association-Nephrology, Dr. Alshamsi brings a wealth of expertise to our discussion. In this episode, we delve into the critical topic of end-stage kidney disease. Dr. Alshamsi provides insights into the challenges faced by patients in this stage of chronic kidney disease, discussing treatment options like dialysis and kidney transplantation. Discover the impact of end-stage kidney disease on overall health and explore recent advancements in nephrology, including precision medicine, wearable devices, and innovations in transplant procedures, offering hope for improved patient outcomes. Join us for a captivating conversation on the complexities of nephrology and the promising developments that shape the future of patient care. Subscribe to MedSynapse for more engaging discussions on the latest medical topics. https://lnkd.in/dKS_QYEE
In-depth Medical Perspectives on End Stage Kidney Didease | Dr. Iman Alshamsi
https://www.youtube.com/
To view or add a comment, sign in
-
In this episode, host Dr. Michael Barraza interviews Dr. Zola N’Dandu, an interventional cardiologist at Ochsner Medical Center in Louisiana, about building a successful critical limb ischemia (CLI) program. Dr. N’Dandu discusses the evolution of CLI in the last decade and how more medications, therapies, and data are now available to support patient care. Advancements such as radial-to-pedal, 3rd and 4th-generation stents, proliferative therapy with stents, drug-coated balloons, and bio-absorbable stents all contribute to redefining the CLI treatment algorithm. Dr. N’Dandu emphasizes that our treatment of no-option-CLI patients needs to change. One of the treatments that he uses for these patients is deep vein arterialization, a technique that was first discovered in 1912 but still has more potential for growth. Full Episode: https://ow.ly/zFuL50Q2aOJ
Building a CLI Program | BackTable VI Podcast
To view or add a comment, sign in
-
Good summary of therapeutic targets in dyslipidemia.
Past President Argentine Lipid Society. Internal Medicine physician and Lipidologist. Pharmacology Professor at FASTA University, School of Medicine.
👉The year in cardiovascular medicine 2023: The top 10 papers in dyslipidaemias ALBERICO CATAPANO Lale Tokgözoğlu European Atherosclerosis Society https://lnkd.in/dFSbKqMS
To view or add a comment, sign in
-
🚨Medical Innovation Alert🚨 "Reinforcing the Aneurysmal Aorta by Additional Layering: Old and New Strategies to Prevent Rupture" - a game-changing exploration in cardiovascular medicine! 💉 Delve into time-tested techniques and pioneering advancements in aortic aneurysm management. 🛡️ Understand how strategic layering fortifies weak aortas, averting life-threatening ruptures. 🔬 Uncover novel insights merging tradition with innovation for improved patient outcomes. Be part of the breakthrough! Scan the QR code or click the link below to access, read, download, and share this pivotal research. 👉 https://lnkd.in/gCkGZcdu Let's collaborate in spreading the word and advancing the frontiers of cardiovascular care. Every share accelerates progress and saves lives! #AorticAneurysm #CardiovascularResearch #MedicalInnovations #PreventiveStrategies #ShareTheKnowledge
To view or add a comment, sign in
-
Explore the world of nephrology with our latest MedSynapse podcast featuring Dr. Iman Alshamsi, a distinguished Nephrology Consultant /Internal Medicine Consultant at SEHA Kidney Care. As a member of the American Society of Nephrology and Emirates Medical Association-Nephrology, Dr. Alshamsi brings a wealth of expertise to our discussion. In this episode, we delve into the critical topic of end-stage kidney disease. Dr. Alshamsi provides insights into the challenges faced by patients in this stage of chronic kidney disease, discussing treatment options like dialysis and kidney transplantation. Discover the impact of end-stage kidney disease on overall health and explore recent advancements in nephrology, including precision medicine, wearable devices, and innovations in transplant procedures, offering hope for improved patient outcomes. Join us for a captivating conversation on the complexities of nephrology and the promising developments that shape the future of patient care. Subscribe to MedSynapse for more engaging discussions on the latest medical topics. https://lnkd.in/dKS_QYEE
In-depth Medical Perspectives on End Stage Kidney Didease | Dr. Iman Alshamsi
https://www.youtube.com/
To view or add a comment, sign in
-
Interventional Cardiologist I Associate Professor of Cardiology I Founder & CEO of Re'im I Editor-Of-Chief of Complex Cases of Structural Heart Intervention I Cedars-Sinai Medical Center, Los Angeles, USA
As we approach an era of treating complex cases of structural interventions predicting unfavorable access anatomy with severe calcification and tortuosity is crucial. The Cedars-Sinai novel model is the most accurate, simple-to-use, and validated model ever published. Please check it. Cedars-Sinai Vivek Patel Yuval Tamir Robert Naami Hasan Jilaihawi Alon Shechter, MD MHA Sharon Shalom Natanzon Danon Kaewkes Raj R. Makkar #Frontiers in Cardiovascular Medicine
To view or add a comment, sign in
-
Our recent study from CMDR!! CMD assessment is safe and requires only slightly additional contrast use (10 mL) and slightly longer fluoroscopy time (2 min) without clinical implications. These findings emphasize the favorable safety and feasibility of invasive CMD assessment. https://lnkd.in/exEpbhFF
Coronary microvascular dysfunction assessment: A comparative analysis of procedural aspects
onlinelibrary.wiley.com
To view or add a comment, sign in
-
🥳Three papers have been published in this Special Issue "Clinical Updates on the #Aortic #Aneurysm and #Aortic #Dissection", thanks very much to our Guest Editors Dr. Benedikt Reutersberg and Dr. Matthias Trenner, and the authors! 🤩Welcome more submissions! Special Issue and submission link: https://lnkd.in/ggnDQZuk ---------------- 📖Read them: [Article] Aortic Vascular Graft and Endograft Infection–Patient Outcome Cannot Be Determined Based on Pre-Operative Characteristics, by Dr. Albert Busch (https://lnkd.in/gsWj4SJX) [Article] Preoperative Imaging Signs of Cerebral Malperfusion in Acute Type A Aortic Dissection: Influence on Outcomes and Prognostic Implications—A 20-Year Experience, by Dr. Mohammed Al-Tawil (https://lnkd.in/gUs9bnwk) [Article] Paracolic Gutter Routing: A Novel Retroperitoneal Extra-Anatomical Repair for Infected Aorto-Iliac Axis †, by Prof. Hazem El Beyrouti (https://lnkd.in/g_kFrj9E) #AorticAneurysm #AorticDissection #Vascular Journal of Clinical Medicine (JCM) MDPI
To view or add a comment, sign in
-
Great article on INOCA- and how to diagnose and treat.
Dynamic Medical Device Sales Leader | Pursuing Masters in Health Care Transformation at University of Texas
“INOCA is not a benign condition.” Alaide Chieffo sits down with Mamas Mamas to describe the clinical population, and the need for better diagnostics and treatment for INOCA patients. Abbott’s Coroflow system is the only comprehensive physiology system in the US that allows for diagnosis for CMD. #cadiovascular #abbottproud #interventionalcardiology
Beyond the Data: Understanding INOCA
tctmd.com
To view or add a comment, sign in